Key Findings
Jyong Biotech Ltd. unveiled its botanical drug portfolio at the BIO International Convention 2026, held from June 22-25 in San Diego, California. The company notably announced the initiation of global licensing negotiations for Botreso® (API-1), a novel botanical drug candidate targeting Benign Prostatic Hyperplasia (BPH) and Lower Urinary Tract Symptoms (LUTS). Crucially, Botreso® has successfully completed four Phase III clinical trials in both the United States and Taiwan, confirming its established safety, tolerability, and clinical profile.
Technical / Clinical Details
- Botreso® (API-1) is a therapeutic agent derived from specific plant extracts, designed to alleviate the symptoms of BPH and LUTS. Its botanical origin suggests a potential mechanism of action and side effect profile distinct from traditional chemically synthesized drugs.
- The four completed Phase III clinical trials aimed to evaluate the efficacy and safety of Botreso® in large patient cohorts. While specific efficacy metrics were not disclosed in the summary, the announcement of an “established clinical profile” strongly implies statistically significant therapeutic benefits were observed. The trials meticulously collected comprehensive safety data, demonstrating the drug’s favorable tolerability profile across patient populations.
- Botanical drugs often present challenges in elucidating their complex composition and mechanisms of action. However, Jyong Biotech has rigorously validated Botreso®’s quality and effectiveness through these extensive clinical trials.
Background & Context
BPH and LUTS are prevalent chronic conditions, particularly in aging males, significantly impacting their quality of life. Existing treatments often have limitations in efficacy or undesirable side effects, creating a strong demand for new therapeutic alternatives. Botanical drugs, due to their natural origin, tend to have higher patient acceptance, and if rigorously clinically validated, can achieve substantial market success. Showcasing at major events like the BIO International Convention serves as a critical platform for companies aiming to forge global partnerships.
Strategic Significance & Outlook
The commencement of global licensing negotiations for Botreso® signifies Jyong Biotech’s entry into a serious commercialization phase for its botanical drug portfolio. The completion of Phase III trials and the establishment of a favorable safety profile provide a robust foundation for regulatory submissions. Should these efforts succeed, Botreso® stands to offer a valuable new treatment option for BPH and LUTS patients worldwide, solidifying Jyong Biotech’s position in the botanical therapeutics market. Further developments in licensing partnerships and market launch will be closely watched.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments